Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
—
Est. revenue
—
Implied move
±18.6%
EPS beat rate
75%
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases, particularly Duchenne muscular dystrophy (DMD). With a market cap of $2 billion, its work is crucial in addressing unmet medical needs in the healthcare sector.
Last quarter
In Q2 2026, Sarepta reported an EPS of $0.64, exceeding expectations by 88.24%. However, the stock fell 2.81% the next day, indicating some market skepticism despite the strong earnings.
Management promises and guidance
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+47.13%
Avg 1-day reaction
-2.72%
Overall, investors are cautiously optimistic about Sarepta's upcoming earnings, especially given its recent strong EPS performance. However, the lack of revenue guidance raises concerns about future growth.
Bull case
If Sarepta continues to beat EPS estimates and provides positive updates on clinical trials, it could signal strong future growth and boost investor confidence.
Bear case
Conversely, any negative news regarding clinical trials or a miss on EPS could lead to a significant drop in stock price, as seen in past quarters.
Key metrics to watch
Earnings Per Share (EPS)
$0.64EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/ARevenue growth will indicate the company's ability to expand its market presence and validate its product pipeline.
The print will turn on these.
Q1
What is the current status of ongoing clinical trials for DMD treatments?
Updates on clinical trials can significantly influence investor sentiment and the stock price, as they directly relate to the company's future revenue potential.
Q2
Will management provide any revenue guidance for the upcoming quarters?
Clear revenue guidance is crucial for investors to assess the company's growth trajectory and financial health.
Why consensus could be wrong
The Street may be underestimating the potential impact of Sarepta's recent clinical trial successes, which could drive future revenue growth beyond current expectations.
Supporting evidence
Sarepta has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.
Options pricing suggests a significant move, indicating that traders expect volatility and potential positive news.
The recent surge in EPS could indicate a trend that the market has not fully priced in.
Key risk
If clinical trial results exceed expectations, it could dramatically shift market sentiment and expectations.
Pre-commit to what would confirm each case.
The market is debating whether Sarepta can sustain its recent earnings momentum and provide clarity on future revenue growth.
Bull confirmed if
An EPS of $0.70 or higher, along with positive clinical trial updates, would confirm the bull case.
Bear confirmed if
An EPS below $0.60 or negative news regarding clinical trials would confirm the bear case.
What the market is pricing for the move.
Implied Move
±18.61%
Historical Avg
±5.4%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±18.6% while SRPT has averaged ±5.4% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
67.8%
Smart-money positioning from the most recent 13F filings.
Institutional
104.10%
of float
Insider
4.89%
of float
Holders
442
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
18,994,958 sh · $332.4M
17.98%
28.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Sarepta beats expectations, history suggests the stock could rise by around 0.68%, confirming bullish sentiment.
In line / cautious
If results are in line with expectations, the stock may remain flat, reflecting cautious investor sentiment.
Miss
A miss on EPS could lead to a decline of about 12.94%, as seen in past quarters, which would raise concerns about the company's growth prospects.
The lines on the call that would change the story.
Clinical Trial Updates
N/AUpdates on ongoing clinical trials can significantly impact investor sentiment and stock price, especially in biotech.
State Street Corporation
8,916,090 sh · $156.0M
8.44%
34.8%
Vanguard Portfolio Management LLC
8,377,470 sh · $146.6M
7.93%
26.2%
Vanguard Capital Management LLC
4,591,755 sh · $80.4M
4.35%
0.3%
Two Sigma Investments, LP
4,598,735 sh · $80.5M
4.35%
0.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.